Understanding and targeting the immune environment in diffuse large B‑cell lymphoma
Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
['FUNDING_P01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11167610
This project will learn how changes in cell control systems and the surrounding immune cells drive diffuse large B‑cell lymphoma and will work to develop treatments that target that tumor environment for people with DLBCL.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11167610 on ClinicalTrials.gov |
What this research studies
Researchers at Weill Cornell and collaborators will combine patient tumor samples, advanced genetic and epigenetic analyses, and physiologically accurate lab models to map how mutations in chromatin modifiers and transcription factors shape lymphoma cells and their immune niche. They will study how these tumor-intrinsic changes interact with the surrounding immune cells and with host factors such as age. The team will use these insights to test therapeutic strategies that modify epigenetic states or immune signaling to disrupt the supportive tumor microenvironment. Findings are intended to guide future patient-centered therapies and possible clinical approaches.
Who could benefit from this research
Good fit: People diagnosed with diffuse large B‑cell lymphoma, especially those whose tumors carry mutations in chromatin modifier or transcription factor genes or who are being considered for targeted or immune-based therapies, would be most relevant.
Not a fit: People without DLBCL or patients whose lymphoma is driven by unrelated mechanisms may not receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that better target the tumor immune environment and improve outcomes for people with DLBCL.
How similar studies have performed: Previous studies have shown benefit from targeting epigenetic changes and the tumor microenvironment in some blood cancers, but combining these approaches specifically for DLBCL remains an active and partly novel area.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CERCHIETTI, LEANDRO C — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: CERCHIETTI, LEANDRO C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.